Sodium-glucose co-transporter 2 inhibitors – a review article
Journal of Education, Health and Sport, 2019 Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus.
Marcin Makuch +3 more
doaj +4 more sources
Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews [PDF]
Journal of Cardiovascular Development and DiseaseBackground: Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment ...
Yixuan Fang +3 more
doaj +2 more sources
Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
Perspectives in Clinical Research, 2021 Cardiovascular outcome trials (CVOTs) have to be done by sponsors who wish to launch new antidiabetic drugs in the US, since the December 2008 US Food and Drug Administration ruling, which was subsequently accepted by the European Medicines (Evaluation ...
Viraj Ramesh Suvarna
doaj +4 more sources
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease [PDF]
The Scientific World Journal, 2015 SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli +6 more
doaj +4 more sources
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Frontiers in Pharmacology, 2022 Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life.
Yuling Jing +3 more
doaj +3 more sources
Sodium glucose co-transporter 2 inhibitors in heart failure therapy
Türk Kardiyoloji Derneği Arşivi, 2020 Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis.
Yüksel Çavuşoğlu +10 more
doaj +5 more sources
Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Frontiers in OncologyTumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of ...
Jiaqi Wang, Wenyong Yang
doaj +3 more sources
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2022 Background Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk ...
Seung Eun Lee +5 more
doaj +1 more source
Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
Linchuang shenzangbing zazhi, 2023 Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule.
Feng Liu +3 more
doaj +1 more source
Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Australian Prescriber, 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L. +2 more
openaire +3 more sources